Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$2.09 ▼ -0.17
(-7.52%)
MKT CAP: $135.5M • VOL: 562.1K
52W L $1 52W H $6
HSDT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $548.0K | $520.0K | $605.0K |
| YoY Revenue Growth % | +5.4% | -14.0% | — |
| Gross Profit | $5.5M | -$62.0K | — |
| Gross Margin % | 98.0% | -11.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$243.8M | -$13.9M | -$12.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$40.9M | -$11.7M | -$8.9M |
| EBITDA (Normalized) | — | -$13.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$16.5M | -$11.0M | -$10.4M |
| Capital Expenditures (CapEx) | — | $5.0K | — |
| Free Cash Flow (FCF) | -$16.5M | -$11.0M | -$10.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.3M | $1.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $300.9M | $1.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HSDT.